Quick Facts: Archiment Treatment Domains

• Chronic Inflammatory Bowel Conditions: Used in the management of moderately to severely active ulcerative colitis and Crohn's disease.
• Joint and Spinal Conditions: A treatment option for active rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, and psoriatic arthritis.
• Skin Manifestations: Indicated for reducing symptoms associated with chronic severe plaque psoriasis.

---

What Archiment treats: main uses and benefits

Archiment is a prescription medication utilized to address several chronic inflammatory and autoimmune conditions. It is specifically a therapeutic option for individuals managing moderately to severely active Crohn's disease, including pediatric patients who have demonstrated an inadequate response to conventional therapies. It is also an approved treatment for ulcerative colitis, helping to reduce signs and symptoms, maintain remission, and promote mucosal healing in adult and pediatric patients.

In rheumatology, Archiment is a consideration for controlling the symptoms of rheumatoid arthritis, often administered alongside methotrexate. It is further indicated to help reduce the signs and symptoms of ankylosing spondylitis and psoriatic arthritis.

For dermatological use, Archiment is an option for individuals with chronic severe plaque psoriasis. Its role across these therapeutic domains is to help modulate inflammatory processes associated with these conditions, supporting clinical management and symptom relief.

Eligibility Map: Who can and cannot use Archiment — official regulatory information

The eligibility profile for Archiment (Camostat) is strictly governed by population exclusions and conditional use categories established in official regulatory documents.

Category	Official Regulatory Statement
Populations for whom use is allowed:	Adult patients who meet the established inclusion criteria for the authorized indication(s) in their respective regions.
Populations for whom use is not recommended:	Breastfeeding mothers are generally not recommended to use this medicine.
Populations for whom use is contraindicated:	Individuals with a known allergic reaction or severe hypersensitivity to Camostat Mesylate or any component of the drug.
Age-related eligibility rules:	Use is typically not established or is excluded for pediatric patients under 18 years of age.
Condition-specific eligibility rules:	Patients with severe renal impairment (e.g., GFR below 30 mL/min) are generally excluded. Patients with severe hepatic insufficiency are also usually excluded.

---

Resulting Eligibility Structure

The medicine is contraindicated in individuals with a known severe allergy. Explicit exclusion criteria define use as not recommended for pregnant women and breastfeeding mothers. Use is also restricted in populations with severe kidney or liver dysfunction, as these compromised conditions affect the body's ability to eliminate the drug.

Interactions with other medicines and products

The official regulatory documents for Archiment (Camostat Mesylate) define its interaction profile primarily by its low potential to initiate drug-drug interactions through major metabolic pathways.

Category	Official Regulatory Finding
Medicinal product categories with documented interactions	None explicitly listed as requiring interaction management.
Mechanistic basis of interactions	Pharmacokinetic Interaction (Exclusionary): Documented non-inhibition of major CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
Timing-based interaction rules	None documented for interaction risk management (e.g., "administer X hours apart").
Interaction-related restrictions	None documented (e.g., no formal contraindications or use-with-caution restrictions based on interaction risk).

Official Interaction Statements

Archiment and its active metabolite are formally determined not to inhibit the major cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This regulatory finding establishes a minimal potential for Archiment to act as a perpetrator and increase the plasma exposure of co-administered medicines that are metabolized by these pathways. The prescribing information also does not list any medicines as formally contraindicated due to interaction risk. Furthermore, the documents do not specify any mandatory timing separation rules to manage an interaction, nor are there explicit interactions documented with food, alcohol, or supplements that alter the drug's effect. The overall profile defines a low risk for Archiment to alter the pharmacokinetics of co-administered agents based on current regulatory data.

Archiment functions as a direct, selective thrombin inhibitor. Its primary biological target is the enzyme thrombin (Coagulation Factor IIa) within the coagulation cascade. Archiment binds reversibly to the active site of the thrombin molecule, independent of the cofactor Antithrombin III. This molecular interaction prevents the enzyme from performing its procoagulant functions.

Downstream, the inhibition of thrombin blocks its ability to catalyze the conversion of fibrinogen to fibrin, thereby preventing the formation of a stable fibrin clot. Thrombin-mediated activation of Coagulation Factors V, VIII, and XIII is also blocked. Intracellularly, the drug inhibits thrombin-induced platelet aggregation via preventing the cleavage of the protease-activated receptor PAR-1 on the platelet surface. The systemic physiological consequence is a reduction in the rate and extent of coagulation cascade progression, resulting in anticoagulation.

How Archiment is Used in Clinical Practice

Archiment (Camostat Mesylate) is used according to specific administration patterns, primarily focusing on its oral route for systemic absorption. The active ingredient is supplied as a 100 mg tablet, determining the unit size for all labeled regimens.

---

Official Dosing and Schedule

Archiment is administered in divided doses three times daily (TID) to ensure a consistent presence of the drug in the body. The total daily dose varies based on the condition being addressed:

Condition	Standard Total Daily Dose	Frequency
Chronic Pancreatitis	600 mg	Three times daily
Postoperative Reflux Esophagitis	300 mg	Three times daily

The daily amount for Chronic Pancreatitis may be adjusted by the prescriber according to the patient's symptomatic response.

---

Administration Conditions and Continuity

Proper use of Archiment includes specific requirements related to intake timing. For Postoperative Reflux Esophagitis, the total daily dose is structured to be taken after each meal. Instructions for continuity of care include guidance on missed doses; if a dose is missed, the patient is instructed not to compensate by taking a double amount at the next scheduled time. Therapy is typically maintained as part of a long-term plan and must not be discontinued unless advised by a healthcare professional.

Research evidence / Overview of studies for Archiment (Camostat)

This overview describes the types of studies that research examined for Archiment and what findings describe patterns observed in the specific groups of patients evaluated. It focuses on the official research record relied upon by regulatory authorities, without providing clinical advice or treatment recommendations.

---

Evidence for Use in Inflammatory Bowel Conditions (Ulcerative Colitis and Crohn's Disease)

The primary evidence supporting the use of Archiment for Ulcerative Colitis (UC) and Crohn's Disease (CD) was applied in studies examining the initial and maintenance treatment of moderately to severely active UC and CD. These studies are designed to reduce bias by comparing Archiment against a placebo or another treatment in a controlled setting. Researchers explored short-term changes measured during the study period (induction) and the longer-term period (maintenance).

For UC, researchers monitored outcomes reflecting daily functioning or activity level, such as the measurements of clinical remission and signs of healing inside the colon, known as mucosal healing. The study designs focused on patients with moderately to severely active disease who were experiencing conditions involving periods of heightened symptoms. The findings describe patterns observed where patients who were evaluated in these studies reported how symptoms evolved in the observed populations during the defined time intervals.

---

Evidence for Use in Rheumatology and Psoriasis

Archiment was studied for Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), and Chronic Severe Plaque Psoriasis. The primary studies for the rheumatologic conditions were based on Randomized Controlled Trials (RCTs). For RA, the research examined Archiment when it was observed in patients alongside methotrexate, a standard medication. Trials monitored outcomes related to physical discomfort and joint inflammation, with findings describing patterns across standardized measures like the ACR response criteria.

For Psoriasis, large controlled Phase 3 trials examined outcomes linked to inflammatory or irritative states using tools like the PASI score to quantify skin clearance. Reported data included changes in patient-reported outcomes describing perceived discomfort and quality of life.

---

Research Gaps and Areas of Uncertainty

While studies include intermediate-term follow-up, long-term effects are not fully established beyond the periods covered by the major trials. The follow-up durations were limited in comparison to the total lifetime of chronic disease. Furthermore, comparative evidence is lacking from direct head-to-head trials against every other advanced therapy currently available in these treatment areas. Data for certain groups remain insufficient, and the evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. NCT07113522 | A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
2. Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules - Frontiers

Common questions about Archiment (FAQ)

Q: Is Archiment a safe medication?

A: Archiment may be generally well-tolerated, but like all medicines, it carries a risk of side effects. The product information describes a profile of potential risks, including some serious ones. It is important to discuss all potential risks and benefits with a healthcare provider.

---

Q: How long until Archiment starts to work?

A: The time it takes for Archiment to potentially influence symptoms can vary significantly among individuals. Clinical studies or product information may indicate an expected timeline, but this should be discussed with a doctor, as individual response may differ.

---

Q: Can I stop taking Archiment if I feel better?

A: Stopping a prescribed medication, including Archiment, should only be done under the guidance of a healthcare professional. Abruptly discontinuing treatment may be associated with a return of symptoms or withdrawal effects, depending on the drug.

---

Q: Is Archiment better than other treatments?

A: Comparisons between Archiment and other treatment options depend on an individual’s specific health condition and response. Healthcare providers consider various factors, including clinical data and patient history, when determining the most suitable treatment path.

Archiment tablets must be stored according to the conditions documented in official labeling to maintain stability and effectiveness.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store at ambient room temperature, typically 15 C to 30 C.
Protection	Keep in the original container/final package and away from direct sunlight, heat, and moisture.
Child Safety	Must be stored out of the sight and reach of children.

The product is generally stable for three years when stored under these specified ambient conditions.

---

Disposal Instructions

Any unused or expired Archiment must be disposed of in accordance with local regulations.

Regulators recommend utilizing a community drug take-back program as the preferred disposal method. The product should not be disposed of by flushing down the sink or toilet, and the active compound must not be allowed to enter sewers or water systems.